Matteo Megna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8044330/publications.pdf

Version: 2024-02-01

201 papers

3,715 citations

30 h-index 233338 45 g-index

202 all docs 202 docs citations

times ranked

202

3176 citing authors

#	Article	IF	CITATIONS
1	A case of psoriatic alopecia secondary to certolizumab pegol: clinical and trichoscopic evaluation. International Journal of Dermatology, 2023, 62, .	0.5	4
2	Very low-calorie ketogenic diet (VLCKD) in patients with psoriasis and obesity: an update for dermatologists and nutritionists. Critical Reviews in Food Science and Nutrition, 2022, 62, 398-414.	5.4	32
3	Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy. Journal of Dermatological Treatment, 2022, 33, 592-592.	1.1	29
4	Phototherapy and vitamin D: the importance in COVID-19 era. Journal of Dermatological Treatment, 2022, 33, 1165-1165.	1.1	2
5	Secukinumab during pregnancy: a case report and review of literature. Journal of Dermatological Treatment, 2022, 33, 585-586.	1.1	4
6	Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Archives of Dermatological Research, 2022, 314, 619-623.	1.1	39
7	Reply to "Psoriasis exacerbation after COVIDâ€19 vaccination: report of 14 cases from a single centreâ€by Sotiriou E <i>etÂal</i> Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	40
8	Realâ€world evidence of biologic treatments in moderate–severe psoriasis in Italy: Results of the <scp>CANOVA</scp> (<scp>EffeCtiveness</scp> of biologic <scp>treAtmeNts</scp> for plaque) Tj ETQq0 0 0 r	gBT /Over	·logk 10 Tf 50
9	Antiâ€interleukinâ€23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in realâ€world practice. Clinical and Experimental Dermatology, 2022, 47, 561-567.	0.6	55
10	Real world practice indirect comparison between guselkumab and risankizumab: Results from an <scp>Italian</scp> retrospective study. Dermatologic Therapy, 2022, 35, e15214.	0.8	35
11	Eczematous drug eruption in patients with psoriasis under antiâ€interleukinâ€17A: does interleukinâ€22 play a key role?. Clinical and Experimental Dermatology, 2022, 47, 918-925.	0.6	15
12	Psoriasis awareness among general population: preliminary results of an online survey. Italian Journal of Dermatology and Venereology, 2022, 156, .	0.1	2
13	Longâ€ŧerm results of teledermatology for acne patients during COVIDâ€19 pandemic. Journal of Cosmetic Dermatology, 2022, 21, 1356-1357.	0.8	8
14	Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. Journal of Dermatological Treatment, 2022, 33, 2560-2564.	1.1	43
15	Letter to the editor regarding the article "Oguz Topal I, Kara Polat A, Zindancı İ, et al. Adherence to systemic therapy in patients with psoriasis during the COVIDâ€19 pandemic: A multicenter study. J Cosmet Dermatol. 2021;10.1111/jocd.14610.â€. Journal of Cosmetic Dermatology, 2022, 21, 880-882.	0.8	2
16	Ixekizumab in scalp psoriasis: Clinical, dermoscopical, and in vivo reflectance confocal microscopy evaluation. Dermatologic Therapy, 2022, , e15332.	0.8	0
17	Letter to the editor submitted in response to "Should the presence of psoriatic arthritis change how we manage psoriasis?". Journal of Dermatological Treatment, 2022, , 1-3.	1.1	3
18	A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: Should treatment be discontinued?. Dermatologic Therapy, 2022, 35, e15361.	0.8	3

#	Article	IF	Citations
19	Leg paralysis after photodynamic therapy for lymphomatoid papulosis: A case report. Dermatologic Therapy, 2022, 35, e15394.	0.8	2
20	Alopecia universalis improvement following risankizumab in a psoriasis patient. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	8
21	Generalized pustular psoriasis rapidly and successfully treated with ixekizumab in a Caucasian patient. Dermatologic Therapy, 2022, 35, e15382.	0.8	4
22	Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatologic Therapy, 2022, 35, e15378.	0.8	20
23	Acrodermatitis continua of Hallopeau: Is apremilast an efficacious treatment option?. Dermatologic Therapy, 2022, 35, e15423.	0.8	3
24	Impact of fixedâ€dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52â€week randomized, doubleâ€blind, PSO‣ONG trial. Journal of the European Academy of Dermatology and Venereology, 2022, , .	1.3	0
25	Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. Journal of Clinical Medicine, 2022, 11, 1511.	1.0	34
26	Teledermatology: A useful tool also after COVIDâ€19 era?. Journal of Cosmetic Dermatology, 2022, 21, 2309-2310.	0.8	33
27	A Case of Chronic HCV Infection Reactivation in a Psoriasis Patient Treated with Guselkumab. Current Drug Safety, 2022, 17, .	0.3	3
28	Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection. Journal of Dermatological Treatment, 2022, 33, 2629-2633.	1.1	8
29	Risankizumab treatment in psoriasis patients who failed antiâ€IL17: A 52â€week realâ€Iife study. Dermatologic Therapy, 2022, 35, e15524.	0.8	43
30	Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients' Assessment. Clinical, Cosmetic and Investigational Dermatology, 2022, Volume 15, 661-673.	0.8	4
31	Generalized violaceous maculopapular rash and multiple verrucous nodules on the testes: a case of secondary syphilis misdiagnosed as lymphoma. Italian Journal of Dermatology and Venereology, 2022, , .	0.1	O
32	Impact of the <scp>COVID</scp> â€19 pandemic on hospital admissions of patients with rare diseases: an experience of a Southern Italy referral center. International Journal of Dermatology, 2022, 61, .	0.5	28
33	Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection. Clinical Drug Investigation, 2022, 42, 525-531.	1.1	7
34	Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. Journal of Dermatological Treatment, 2022, 33, 2813-2820.	1.1	57
35	Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. Clinical and Experimental Dermatology, 2022, 47, 1863-1864.	0.6	31
36	Reply to  Development of severe pemphigus vulgaris following <scp>SARS oV</scp> â€2 vaccination with <scp>BNT162b2</scp> ' by Solimani <i>et al</i> Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	25

#	Article	IF	CITATIONS
37	Treating psoriasis in the elderly: biologics and small molecules. Expert Opinion on Biological Therapy, 2022, 22, 1503-1520.	1.4	30
38	Adalimumab biosimilar in a pediatric patient: Clinical and in vivo reflectance confocal microscopy evaluation. Dermatologic Therapy, 2022, 35, .	0.8	2
39	Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian singleâ€center retrospective study in a realâ€life setting. Dermatologic Therapy, 2022, 35, .	0.8	28
40	A Critical Reappraisal of Off-Label Use of Photodynamic Therapy for the Treatment of Non-Neoplastic Skin Conditions. Dermatology, 2021, 237, 262-276.	0.9	15
41	Mycoses in the elderly population: what a 16â€year experience has taught us. International Journal of Dermatology, 2021, 60, e60-e62.	0.5	0
42	QuantiFERON TBâ€gold conversion rate among psoriasis patients under biologics: a 9â€year retrospective study. International Journal of Dermatology, 2021, 60, 352-357.	0.5	13
43	Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti― <scp>interleukin</scp> â€17 treatment: A realâ€life 52â€week retrospective study. Dermatologic Therapy, 2021, 34, e14673.	0.8	45
44	Is there any association between psoriasis, psoriatic arthritis and thyroid autoimmunity?. Australasian Journal of Dermatology, 2021, 62, e207-e211.	0.4	5
45	Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review. Dermatologic Therapy, 2021, 34, e14857.	0.8	14
46	Pityriasis versicolor with uncommon localizations. Giornale Italiano Di Dermatologia E Venereologia, 2021, 155, 786-787.	0.8	1
47	An indolent nasal form of primary cutaneous CD8â€positive peripheral Tâ€ell lymphoma not otherwise specified successfully treated with local radiation therapy: A new subtype?. Dermatologic Therapy, 2021, 34, e14887.	0.8	1
48	Itraconazoleâ€induced photodistributed erythema multiforme. Dermatologic Therapy, 2021, 34, e14901.	0.8	2
49	Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in Psoriasis. Journal of Clinical Medicine, 2021, 10, 1031.	1.0	19
50	Is It Possible to Improve Scabies Diagnosis Performance?. Dermatology Practical and Conceptual, 2021, 11, e2021015.	0.5	1
51	Ciprofloxacinâ€induced symmetrical drugâ€related intertriginous and flexural exanthema (<scp>SDRIFE</scp>) in a psoriasis patient. Contact Dermatitis, 2021, 85, 467-469.	0.8	3
52	Realâ€world experience versus clinical trials: pros and cons in psoriasis therapy evaluation. International Journal of Dermatology, 2021, , .	0.5	12
53	Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?. Dermatologic Therapy, 2021, 34, e15030.	0.8	27
54	Ultraviolet radiation, vitamin D, and COVID-19. Italian Journal of Dermatology and Venereology, 2021, 156, 366-373.	0.1	3

#	Article	IF	CITATIONS
55	A case of pediatric psoriasis successfully and rapidly treated with ixekizumab. Dermatologic Therapy, 2021, 34, e15108.	0.8	5
56	Hidradenitis Suppurativa: Where We Are and Where We Are Going. Cells, 2021, 10, 2094.	1.8	50
57	Onset of vitiligo in a psoriasis patient on ixekizumab. Dermatologic Therapy, 2021, 34, e15102.	0.8	31
58	Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison. Journal of the American Academy of Dermatology, 2021, 85, 1028-1030.	0.6	33
59	Biologic Therapies, Psoriasis, and COVID-19: Our Experience at the Psoriasis Unit of the University of Naples Federico II. Dermatology, 2021, 237, 13-14.	0.9	14
60	New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?. Biomedicines, 2021, 9, 1482.	1.4	31
61	Impact of current antipsoriatic systemic treatments on male and female fertility: what endocrinologists need to know. Minerva Endocrinology, 2021, 46, 350-362.	0.6	3
62	Letter to the editor regarding article "Yaliciâ€Armagan B, Tabak GH, Doganâ€Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVIDâ€19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1–5― Journal of Cosmetic Dermatology, 2021, 20, 4073-4075.	0.8	6
63	A case of erythrodermic psoriasis successfully treated with apremilast. Dermatologic Therapy, 2021, , e15204.	0.8	1
64	Cutaneous sarcoidosis small-fiber neuropathy resembling leprosy. Italian Journal of Dermatology and Venereology, 2021, 156, 261-263.	0.1	0
65	A 16-year real-life study on the prevalence of mycoses in a pediatric population. Italian Journal of Dermatology and Venereology, 2021, 156, 503-504.	0.1	0
66	Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. Journal of Dermatological Treatment, 2020, 31, 476-483.	1.1	23
67	Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1â€year period. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e152-e153.	1.3	13
68	Cutaneous melanoma associated with naevi prevalence: A 15â€year crossâ€sectional retrospective study. Australasian Journal of Dermatology, 2020, 61, 39-42.	0.4	5
69	Eczematous reaction to ixekizumab successfully treated with dupilumab. Dermatologic Therapy, 2020, 33, e13218.	0.8	9
70	Psoriasis and atopic dermatitis: different entities with unsolved challenges. British Journal of Dermatology, 2020, 183, 12-12.	1.4	0
71	Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases. Dermatologic Therapy, 2020, 33, e14351.	0.8	3
72	The Role of Thermal Water in Chronic Skin Diseases Management: A Review of the Literature. Journal of Clinical Medicine, 2020, 9, 3047.	1.0	29

#	Article	IF	Citations
73	Holistic approach to psoriasis patient: What about epicardial fat tissue?. Medical Hypotheses, 2020, 143, 110123.	0.8	1
74	Skin Needling in Combination with Antimicrobial Peptides for the Treatment of Keloids: A Novel Perspective Proposal and Approach for Skin Scars. Dermatology, 2020, 236, 601-602.	0.9	2
75	A Case of Steatocystoma Multiplex in a Psoriatic Patient during Treatment with Anti-IL-12/23. Skin Appendage Disorders, 2020, 6, 309-311.	0.5	1
76	A case of erythrodermic psoriasis successfully treated with guselkumab. Dermatologic Therapy, 2020, 33, e13238.	0.8	30
77	Hidradenitis Suppurativa in a Patient Affected by Mayer-Rokitansky-Kýster-Hauser Syndrome: Insight into the Role of Hormones in HS. Skin Appendage Disorders, 2020, 6, 366-369.	0.5	2
78	Giant nodular melanoma of the nose in a 78â€yearâ€old female refusing complete excision. Dermatologic Therapy, 2020, 33, e14056.	0.8	1
79	Efficacy and safety of risankizumab in psoriasis patients who failed <scp>antiâ€IL</scp> â€17, antiâ€12/23 and/or anti <scp>IL</scp> â€23: Preliminary data of a realâ€life 16â€week retrospective study. Dermatologic Therapy, 2020, 33, e14144.	0.8	44
80	Dermoscopic patterns of intradermal naevi. Australasian Journal of Dermatology, 2020, 61, 337-341.	0.4	11
81	Management of biological therapies for chronic plaque psoriasis during COVIDâ€19 emergency in Italy. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e770-e772.	1.3	31
82	Etanercept for pediatric acrodermatitis continua of Hallopeau: A case report and literature review. Dermatologic Therapy, 2020, 33, e14046.	0.8	1
83	Chronic inflammatory skin diseases and biologics: what to expect after COVIDâ€19 pandemic?. International Journal of Dermatology, 2020, 59, 1144-1145.	0.5	3
84	Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. Journal of Dermatological Treatment, 2020, , 1-5.	1.1	39
85	Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. PLoS ONE, 2020, 15, e0237267.	1.1	19
86	Erythrodermic pityriasis rubra pilaris treatment: Two case reports and literature review. Dermatologic Therapy, 2020, 33, e14223.	0.8	2
87	A Case of Ofuji Disease Successfully Treated with the Combination of Low-Dose Indomethacin and Topical Tacrolimus. Case Reports in Dermatology, 2020, 12, 155-158.	0.3	5
88	Immunocytometric analysis of COVID patients: A contribution to personalized therapy?. Life Sciences, 2020, 261, 118355.	2.0	32
89	COVIDâ€19 pandemic: University of Naples Federico II Dermatology's model of dermatology reorganization. International Journal of Dermatology, 2020, 59, e239-e240.	0.5	5
90	Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?. International Journal of Dermatology, 2020, 59, e308-e309.	0.5	7

#	Article	IF	Citations
91	Realâ€life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2â€year period. Clinical and Experimental Dermatology, 2020, 45, 848-852.	0.6	19
92	May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions?. Medical Hypotheses, 2020, 143, 109853.	0.8	33
93	Certolizumab for the treatment of psoriasis and psoriatic arthritis: a realâ€world multicentre Italian study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2839-2845.	1.3	6
94	Teledermatology for patient management, dermatology education and research during the COVIDâ€19 pandemic. Australasian Journal of Dermatology, 2020, 61, e471-e472.	0.4	6
95	QuantiFERONâ€TB Gold conversion is not uncommon in patients with psoriasis undergoing antiâ€tumour necrosis factor‣ therapy. British Journal of Dermatology, 2020, 183, 977-978.	1.4	5
96	Teledermatology for acne during COVIDâ€19: high patients' satisfaction in spite of the emergency. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e662-e663.	1.3	52
97	Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data. Expert Review of Clinical Immunology, 2020, 16, 599-620.	1.3	19
98	Teledermatology and chronic skin diseases: Real life experience in a Southern Italian Dermatologic Centre. Dermatologic Therapy, 2020, 33, e13839.	0.8	34
99	lxekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa. Dermatologic Therapy, 2020, 33, e13756.	0.8	32
100	The new differential diagnostic test for the lichenoid drug eruption. Dermatologic Therapy, 2020, 33, e13784.	0.8	4
101	Ultrasound: an indispensable tool to evaluate the outcome of surgical approaches in patients affected by hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e413-e414.	1.3	13
102	A case of generalized granuloma annulare successfully treated by hydroxychloroquine. Dermatologic Therapy, 2020, 33, e13894.	0.8	2
103	A case of pediatric acrodermatitis continua of Hallopeau successfully treated with adalimumab biosimilar. Dermatologic Therapy, 2020, 33, e13327.	0.8	3
104	Apremilast efficacy and safety in elderly psoriasis patients over a 48â€week period. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e705-e707.	1.3	16
105	Biologics for psoriasis in <scp>COVID</scp> ‶9 era: What do we know?. Dermatologic Therapy, 2020, 33, e13467.	0.8	20
106	May IL-17 have a role in COVID-19 infection?. Medical Hypotheses, 2020, 140, 109749.	0.8	47
107	A case of severe psoriasis in a 84â€yearâ€old women successfully treated with ixekizumab. Dermatologic Therapy, 2020, 33, e13299.	0.8	3
108	Face the COVIDâ€19 emergency: measures applied in an Italian Dermatologic Clinic. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e249.	1.3	29

#	Article	IF	Citations
109	Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. Journal of Dermatological Treatment, 2020, 31, 328-329.	1.1	41
110	Vitamin D and psoriasis: an update for dermatologists and nutritionists. Minerva Endocrinologica, 2020, 45, 138-147.	1.7	26
111	Coronavirus disease and dermatology: current and future challenges. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 683-684.	0.8	O
112	Realâ€ife effectiveness of biological drugs on psoriatic difficultâ€toâ€treat body regions: scalp, palmoplantar area and lower limbs. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e22-e23.	1.3	13
113	Letter to the editor submitted in response to "psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumabâ€. Journal of Dermatological Treatment, 2019, 30, 309-309.	1.1	9
114	<scp>PUVA</scp> and interferon î±2b combined therapy for patients with mycosis fungoides at different stages of the disease: a sevenâ€year retrospective study in Russia. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e72-e74.	1.3	4
115	A case of Stewart–Treves Syndrome of the lower limbs: The usefulness of dermoscopy. International Wound Journal, 2019, 16, 1237-1238.	1.3	2
116	Paracetamolâ€induced symmetrical drugâ€related intertriginous and flexural exanthema (SDRIFE) in a psoriasis patient receiving apremilast therapy. Contact Dermatitis, 2019, 81, 451-454.	0.8	7
117	Petechia of the Penis: Sexual Habits or Adverse Drug Reaction?. Current Urology, 2019, 12, 167-168.	0.4	2
118	Age and gender influence on HIDRAdisk outcomes in adalimumabâ€treated hidradenitis suppurativa patients. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 25-27.	1.3	7
119	Long-Term Efficacy of Vismodegib After its Withdrawal and Patients' Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI). Dermatology and Therapy, 2019, 9, 719-724.	1.4	23
120	Secukinumab and hidradenitis suppurativa: Friends or foes?. JAAD Case Reports, 2019, 5, 184-187.	0.4	33
121	Kaposi varicelliform eruption induced by methotrexate in an adult atopic dermatitis patient. Dermatologic Therapy, 2019, 32, e12826.	0.8	3
122	Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opinion on Biological Therapy, 2019, 19, 855-861.	1.4	41
123	Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. Journal of the American Academy of Dermatology, 2019, 81, 273-275.	0.6	39
124	Hypersensitivity reaction to certolizumab pegol in a patient affected by psoriatic arthritis. Dermatologic Therapy, 2019, 32, e12900.	0.8	2
125	Intralesional Methotrexate for the Treatment of Keratoacanthoma: The Neapolitan Experience. Dermatology and Therapy, 2019, 9, 369-372.	1.4	14
126	Eczematous eruption during antiâ€interleukin 17 treatment of psoriasis: an emerging condition. British Journal of Dermatology, 2019, 181, 604-606.	1.4	43

#	Article	IF	CITATIONS
127	Psoriasis and skin pain: realâ€life effectiveness of calcipotriol ⟨i⟩plus⟨ i⟩ betamethasone dipropionate in aerosol foam formulation. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1312-1315.	1.3	15
128	Psoriasis in a cohort of patients with common variable immunodeficiency. British Journal of Dermatology, 2019, 180, 935-936.	1.4	6
129	A case of erythrodermic psoriasis successfully treated with ixekizumab. Dermatologic Therapy, 2019, 32, e12825.	0.8	9
130	Melanoma frequency among symmetrical Spitzoid-looking lesions: a retrospective study. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 26-31.	0.8	5
131	Hailey-Hailey disease successfully treated with vitamin D oral supplementation. Dermatologic Therapy, 2019, 32, e12767.	0.8	7
132	Cutaneous leucocytoclastic vasculitis during secukinumab treatment. Italian Journal of Dermatology and Venereology, 2019, , .	0.1	4
133	Italian Guidelines in diagnosis and treatment of alopecia areata. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 609-623.	0.8	39
134	Juvenile amyopathic dermatomyositis. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 215-216.	0.8	0
135	Psoriasis Features in Patients with Inflammatory Bowel Disease. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 1001-1003.	0.1	1
136	Pyoderma gangrenosum successfully treated with topical tacrolimus. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 361-363.	0.8	2
137	Aquagenic wrinkling of the palms. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 364-366.	0.8	0
138	Possible role of BMPâ€'4 in the hyperâ€'pigmentation of psoriatic plaques after antiâ€'TNFâ€'α treatment. Experimental and Therapeutic Medicine, 2019, 18, 4120-4124.	0.8	5
139	Guselkumab for the treatment of psoriasis. Expert Opinion on Biological Therapy, 2018, 18, 459-468.	1.4	33
140	Psoriatic disease treatment nowadays: unmet needs among the "jungle of biologic drugs and small molecules― Clinical Rheumatology, 2018, 37, 1739-1741.	1.0	42
141	Chronic inducible urticarias in children. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1391-1393.	2.0	2
142	Coffee consumption, metabolic syndrome and clinical severity of psoriasis: good or bad stuff?. Archives of Toxicology, 2018, 92, 1831-1845.	1.9	49
143	The effect of smartphone addiction on hand joints in psoriatic patients: an ultrasoundâ€based study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 73-78.	1.3	16
144	A Case of the Co-Existence of Subcorneal Pustular Dermatosis and Pyoderma Gangrenosum and a Review of the Literature. Open Access Macedonian Journal of Medical Sciences, 2018, 6, 1271-1274.	0.1	9

#	Article	IF	CITATIONS
145	Treatment of Atopic Dermatitis with Biologic Drugs. Dermatology and Therapy, 2018, 8, 527-538.	1.4	31
146	Limitations of current monoclonal antibodies for plaque-type psoriasis and an outlook for the future. Expert Opinion on Biological Therapy, 2018, 18, 605-607.	1.4	13
147	Acne prevalence in 9 to 14â€yearâ€old old patients attending pediatric ambulatory clinics in Italy. International Journal of Dermatology, 2018, 57, 1320-1323.	0.5	10
148	Smartphone and video games overuse effects on hand joints: time for screening interventions?. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e457-e458.	1.3	1
149	Skin diseases and tattoos: a five-year experience. Giornale Italiano Di Dermatologia E Venereologia, 2018, 153, 644-648.	0.8	10
150	Psoriasis and high school students: an educational approach. Giornale Italiano Di Dermatologia E Venereologia, 2018, 153, 632-635.	0.8	2
151	Neutrophilic Dermatosis in Pregnancy: An Uncommon Course. Open Access Macedonian Journal of Medical Sciences, 2018, 6, 2393-2394.	0.1	1
152	The effects of etanercept on replication, proliferation, survival, and apoptosis markers in moderate to severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e9-e11.	1.3	3
153	Soccer helps in controlling the development of psoriasis in Italian second league players. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e212-e214.	1.3	6
154	Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 195-205.	2.6	170
155	The role of histological presentation in erythroderma. International Journal of Dermatology, 2017, 56, 400-404.	0.5	9
156	An Italian multicentre study on adult atopic dermatitis: persistent versus adult-onset disease. Archives of Dermatological Research, 2017, 309, 443-452.	1.1	56
157	Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study. Clinical Rheumatology, 2017, 36, 1589-1593.	1.0	12
158	Systemic Treatment of Adult Atopic Dermatitis: A Review. Dermatology and Therapy, 2017, 7, 1-23.	1.4	111
159	Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review. Skin Appendage Disorders, 2017, 3, 95-110.	0.5	53
160	Systemic treatment for psoriasis and malignancies: A real risk?. Dermatologic Therapy, 2017, 30, e12508.	0.8	7
161	Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clinical, Cosmetic and Investigational Dermatology, 2017, Volume 10, 105-115.	0.8	143
162	Adult Atopic Dermatitis: Less Certainty, More Challenges. Journal of Investigational Allergology and Clinical Immunology, 2017, 27, 276-277.	0.6	3

#	Article	IF	CITATIONS
163	Adipose Tissue and Cutaneous Inflammation. , 2017, , 219-238.		3
164	"Active" photoprotection: sunscreens with DNA repair enzymes. Italian Journal of Dermatology and Venereology, 2017, 152, 302-307.	0.1	10
165	SkIndia Quiz 32: A strange sessile formation appearing as a penis-like structure. Indian Dermatology Online Journal, 2017, 8, 68.	0.2	0
166	Psoriasis in melanoma patients: a prospective pilot study. Italian Journal of Dermatology and Venereology, 2017, 152, 109-116.	0.1	1
167	Waste exposure and skin diseases. Italian Journal of Dermatology and Venereology, 2017, 152, 379-382.	0.1	4
168	Chronic hand eczema: is IL-36 \hat{l}_{\pm} helpful in diagnosis and classification?. Italian Journal of Dermatology and Venereology, 2017, 152, 578-585.	0.1	2
169	Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study. Clinical and Experimental Rheumatology, 2017, 35, 137-140.	0.4	17
170	Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clinical and Experimental Dermatology, 2016, 41, 564-566.	0.6	45
171	Photodynamic Therapy and Skin Appendage Disorders: A Review. Skin Appendage Disorders, 2016, 2, 166-176.	0.5	24
172	Psoriatic arthritis and psoriasis: differential diagnosis. Clinical Rheumatology, 2016, 35, 1893-1901.	1.0	64
173	Systemic Treatment of Pediatric Psoriasis: A Review. Dermatology and Therapy, 2016, 6, 125-142.	1.4	69
174	Rejuvenative Outcomes for the Lip and Eye Area. , 2016, , 7-14.		0
175	The risk of herpes zoster in patients with psoriasis: A retrospective records-based observational study. Indian Journal of Dermatology, Venereology and Leprology, 2016, 82, 744.	0.2	4
176	Appearances may be deceiving. Dermatology Practical and Conceptual, 2016, 6, 1-3.	0.5	1
177	Adult atopic dermatitis: a review. Giornale Italiano Di Dermatologia E Venereologia, 2016, 151, 403-11.	0.8	34
178	What's new about atopic dermatitis and sporting activity. Giornale Italiano Di Dermatologia E Venereologia, 2016, 151, 219-20.	0.8	2
179	Psoriasis in elderly and non-elderly population: clinical and molecular features. Giornale Italiano Di Dermatologia E Venereologia, 2016, 151, 587-595.	0.8	15
180	Aquagenic wrinkling of the palms: a case report and literature review. Dermatology Online Journal, 2016, 22, .	0.2	0

#	Article	IF	CITATIONS
181	Psoriasis in Children: A Review. Current Pediatric Reviews, 2015, 11, 10-26.	0.4	42
182	Insulin Resistance and Skin Diseases. Scientific World Journal, The, 2015, 2015, 1-11.	0.8	74
183	Psoriasis and Skin Pain: Instrumental and Biological Evaluations. Acta Dermato-Venereologica, 2015, 95, 432-438.	0.6	36
184	Anterior Cervical Hypertrichosis: A Case Report and Review of the Literature. Pediatric Dermatology, 2015, 32, 252-255.	0.5	9
185	Psoriasis and sport: a new ally?. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 515-520.	1.3	34
186	Nonalcoholic fatty liver disease, spleen and psoriasis: New aspects of low-grade chronic inflammation. World Journal of Gastroenterology, 2015, 21, 6892-6897.	1.4	47
187	Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-α agents. Giornale Italiano Di Dermatologia E Venereologia, 2015, 150, 731-9.	0.8	17
188	Effects of climate changes on skin diseases. Expert Review of Anti-Infective Therapy, 2014, 12, 171-181.	2.0	46
189	Mammalian Target of Rapamycin in Inflammatory Skin Conditions. European Journal of Inflammation, 2014, 12, 341-350.	0.2	18
190	Melanocytic Nevi in Children of Southern Italy: Dermoscopic, Constitutional, and Environmental Factors. Pediatric Dermatology, 2014, 31, 38-42.	0.5	7
191	Educational and motivational support service: a pilot study for mobile-phone-based interventions in patients with psoriasis. British Journal of Dermatology, 2013, 168, 201-205.	1.4	91
192	Garbage and skin diseases related risk: TableÂ1. Occupational and Environmental Medicine, 2013, 70, 212-212.	1.3	1
193	The risk of herpes zoster in the anti-TNF- \hat{l}_{\pm} era: a case report and review of the literature. Journal of Dermatological Case Reports, 2013, 7, 1-4.	1.1	16
194	Climate change and skin. Giornale Italiano Di Dermatologia E Venereologia, 2013, 148, 135-46.	0.8	13
195	Psoriasis or "psoriases"?. Giornale Italiano Di Dermatologia E Venereologia, 2013, 148, 649-50.	0.8	7
196	Patient-physician relationship in patients with psoriasis. Indian Journal of Dermatology, Venereology and Leprology, 2012, 78, 228.	0.2	25
197	Primary bilateral malignant melanoma of the lower limbs. Dermatology Reports, 2011, 3, 20.	0.4	0
198	Anti-Tumor Necrosis Factor- \hat{l}_{\pm} Therapy in the Management of Psoriasis and B-Chronic Lymphocytic Leukemia. Case Reports in Dermatology, 2011, 3, 60-63.	0.3	13

MATTEO MEGNA

#	Article	lF	CITATIONS
199	Meyerson Phenomenon Around Naevi: Resolution After Sun Exposure?. Acta Dermato-Venereologica, 2011, 91, 352-353.	0.6	O
200	Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge. Psoriasis: Targets and Therapy, 0, Volume 12, 127-137.	1.2	24
201	Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study. Psoriasis: Targets and Therapy, 0, Volume 12, 205-212.	1.2	15